Literature DB >> 23667279

Partially hidden Markov model for time-varying principal stratification in HIV prevention trials.

James Y Dai1, Peter B Gilbert, Benoît R Mâsse.   

Abstract

It is frequently of interest to estimate the intervention effect that adjusts for post-randomization variables in clinical trials. In the recently completed HPTN 035 trial, there is differential condom use between the three microbicide gel arms and the No Gel control arm, so that intention to treat (ITT) analyses only assess the net treatment effect that includes the indirect treatment effect mediated through differential condom use. Various statistical methods in causal inference have been developed to adjust for post-randomization variables. We extend the principal stratification framework to time-varying behavioral variables in HIV prevention trials with a time-to-event endpoint, using a partially hidden Markov model (pHMM). We formulate the causal estimand of interest, establish assumptions that enable identifiability of the causal parameters, and develop maximum likelihood methods for estimation. Application of our model on the HPTN 035 trial reveals an interesting pattern of prevention effectiveness among different condom-use principal strata.

Entities:  

Keywords:  causal inference; direct effect; microbicide; posttreatment variables

Year:  2012        PMID: 23667279      PMCID: PMC3649016          DOI: 10.1080/01621459.2011.643743

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  21 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Identifiability and exchangeability for direct and indirect effects.

Authors:  J M Robins; S Greenland
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

3.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 4.  Risk compensation: the Achilles' heel of innovations in HIV prevention?

Authors:  Michael M Cassell; Daniel T Halperin; James D Shelton; David Stanton
Journal:  BMJ       Date:  2006-03-11

5.  Methodology for Evaluating a Partially Controlled Longitudinal Treatment Using Principal Stratification, With Application to a Needle Exchange Program.

Authors:  Constantine E Frangakis; Ronald S Brookmeyer; Ravi Varadhan; Mahboobeh Safaeian; David Vlahov; Steffanie A Strathdee
Journal:  J Am Stat Assoc       Date:  2004-03       Impact factor: 5.033

Review 6.  Female-controlled methods to prevent sexual transmission of HIV.

Authors:  C J Elias; C Coggins
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

7.  Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Authors:  Salim S Abdool Karim; Barbra A Richardson; Gita Ramjee; Irving F Hoffman; Zvavahera M Chirenje; Taha Taha; Muzala Kapina; Lisa Maslankowski; Anne Coletti; Albert Profy; Thomas R Moench; Estelle Piwowar-Manning; Benoît Mâsse; Sharon L Hillier; Lydia Soto-Torres
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

8.  Some design issues in trials of microbicides for the prevention of HIV infection.

Authors:  Thomas R Fleming; Barbra A Richardson
Journal:  J Infect Dis       Date:  2004-07-20       Impact factor: 5.226

9.  Construction of multilocus genetic linkage maps in humans.

Authors:  E S Lander; P Green
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  Update: barrier protection against HIV infection and other sexually transmitted diseases.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-08-06       Impact factor: 17.586

View more
  2 in total

1.  Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.

Authors:  James Y Dai; Craig W Hendrix; Barbra A Richardson; Cliff Kelly; Mark Marzinke; Z Mike Chirenje; Jeanne M Marrazzo; Elizabeth R Brown
Journal:  J Infect Dis       Date:  2015-06-29       Impact factor: 5.226

2.  Identification and estimation of survivor average causal effects.

Authors:  Eric J Tchetgen Tchetgen
Journal:  Stat Med       Date:  2014-05-29       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.